Study Of Perennial Allergic Rhinitis

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Rhinitis, Allergic, Seasonal

Treatments: Drug: GW685698

Study type: Interventional

Funder types: Industry

Identifiers

NCT00358475

FFR100688

Details and patient eligibility

About

This study was designed to assess safety of an investigational nasal spray in the treatment of perennial allergic rhinitis. Perennial allergic rhinitis is triggered by house dust, mite and mold etc. Typical symptoms are sneezing, nasal congestion and pruritus and rhinorrhea.

Enrollment: 65 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent.
• Outpatient.
• Diagnosis of perennial allergic rhinitis with symptoms.
• Able to comply with study procedures.

Exclusion criteria

• Significant concomitant medical condition.
• Use of corticosteroids/allergy medications.
• Laboratory abnormality.
• Positive pregnancy test.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)